 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
7 News |  |
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Somatuline LA (lanreotide suspension intramuscular) / Ipsen
New P3 trial: Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula (clinicaltrials.gov) - Feb 4, 2025
P3, N=274, Not yet recruiting, Sponsor: SWOG Cancer Research Network
- | Somatuline LA (lanreotide suspension intramuscular) / Ipsen, Teijin
Journal: Quantitative analysis of therapeutic peptides by CZE using multiple sample injection in hydrodynamically closed separation system. (Pubmed Central) - May 13, 2024
The developed methods were also evaluated according to the novel blue applicability grade index, revealing their superior applicability. The results collectively point out the potential of the proposed methods for both quality control and clinical investigations.
- ||| Somatuline LA (lanreotide suspension intramuscular) / Ipsen, Teijin
No me ha quedado muy clara la respuesta a una de las oyentes, qué papel ejerce la somatulina en un tumor no funcionante? (Twitter) - Nov 10, 2022
- ||| Somatuline LA (lanreotide suspension intramuscular) / Ipsen, Teijin
@drenriquegrande Una pregunta, me están poniendo somatulina cada 28 días por un NET, y la próxima me coincide el mismo día que la segunda dosis de la vacuna del covid. Hay problema o debería cambiar la somatulina a otro día? Gracias (Twitter) - Jun 3, 2021
- || Somatuline LA (lanreotide suspension intramuscular) / Ipsen, Teijin
@drenriquegrande hola, pregunta, net grado 1 tratamiento somatulina, puede reducirse? Tratamiento de por vida? Esperanza de vida? (Twitter) - Sep 5, 2020
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Somatuline LA (lanreotide suspension intramuscular) / Ipsen, Teijin
Retrospective data, Journal: ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly. (Pubmed Central) - Dec 20, 2019
The results collectively point out the potential of the proposed methods for both quality control and clinical investigations. Real-life treatment with lanreotide Autogel resulted in early hormonal control in responding patients, with high treatment adherence and satisfaction despite disparity in starting doses and dosing intervals.
- || Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, Journal: Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis. (Pubmed Central) - Nov 22, 2019
P=N/A
Real-life treatment with lanreotide Autogel resulted in early hormonal control in responding patients, with high treatment adherence and satisfaction despite disparity in starting doses and dosing intervals. Lanreotide was associated with significant reductions in drug-delivery time compared to octreotide LAR, which contributed to an improvement in overall healthcare efficiency.